Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.

This study provides valuable findings that MK2 inhibitor CMPD1 can inhibit the growth, migration and invasion of breast cancer cells both in vitro and in vivo. The evidence supporting the claims of ...

NS-229 is an investigational selective Janus kinase 1 (JAK1) inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation. A global, randomized, double-blind ...

BCR-ABL is a type of protein known as a tyrosine kinase. Drugs known as tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the most common treatment for CML. These drugs seem to work best when ...

SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits on the evolution and progression of cardiomyopathy and nephropathy, which is characterized by a reduction in ...

Efficacy was consistent regardless of background therapy. Patients taking nerandomilast, an oral phosphodiesterase 4B (PDE4B) inhibitor, also experienced numerically fewer acute exacerbations ...

Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures to high-potential targets like VEGF, BioSpace explores what’s on the ...

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China State Key Laboratory of Anti-Infective Drug Discovery ...

Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a mechanism different than approved antifibrotic treatments pirfenidone ...